Protalix BioTherapeutics (PLX) Non Operating Income (2012 - 2026)
Protalix BioTherapeutics' (PLX) quarterly Non Operating Income came in at -$5000.0 in Q1 2026, down 101.21% year-on-year from $413000.0 in Q1 2025, and up 95.76% quarter-over-quarter from -$118000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Non Operating Income (2012 - 2026) Analysis & Trends
Protalix BioTherapeutics' Non Operating Income history runs 15 years deep, the most recent figure standing at -$5000.0 for Q1 2026.
- On a quarterly basis, Non Operating Income fell 101.21% year-over-year to -$5000.0 in Q1 2026; TTM through Mar 2026 was -$526000.0, a 199.81% decrease from a year earlier, with the FY2025 full-year figure at -$108000.0, down 145.57% from the prior year.
- Non Operating Income climbed to -$5000.0 in Q1 2026 per PLX's latest filing, from -$118000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $413000.0 in Q1 2025 and bottomed at -$811000.0 in Q4 2023.
- The 5-year median for Non Operating Income is -$118000.0 (2025), against an average of -$185470.6.
- Across the five-year window, Non Operating Income plunged 507.37% in 2023 and surged 235.77% in 2025, its largest moves.
- Year by year, Non Operating Income stood at -$715000.0 in 2022, then declined by 13.43% to -$811000.0 in 2023, then soared by 113.19% to $107000.0 in 2024, then tumbled by 210.28% to -$118000.0 in 2025, then soared by 95.76% to -$5000.0 in 2026.
- Per Business Quant, the three latest PLX Non Operating Income figures stand at -$5000.0 (Q1 2026), -$118000.0 (Q4 2025), and $108000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn | -5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,000.00 |
| Dec 31, 2025 | -118,000.00 |
| Sep 30, 2025 | 108,000.00 |
| Jun 30, 2025 | -511,000.00 |
| Mar 31, 2025 | 413,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Sep 30, 2024 | -148,000.00 |
| Jun 30, 2024 | 155,000.00 |
| Mar 31, 2024 | 123,000.00 |
| Dec 31, 2023 | -811,000.00 |
| Sep 30, 2023 | 168,000.00 |
| Jun 30, 2023 | -774,000.00 |
| Mar 31, 2023 | -477,000.00 |
| Dec 31, 2022 | -715,000.00 |
| Sep 30, 2022 | -442,000.00 |
| Jun 30, 2022 | 190,000.00 |
| Mar 31, 2022 | -416,000.00 |
| Dec 31, 2021 | -910,000.00 |
| Sep 30, 2021 | -2.31 Mn |
| Jun 30, 2021 | -2.08 Mn |